Lipopeptides, focusing on daptomycin, for the treatment of Gram-positive infections

Bibliography

• Cubicin (daptomycin for injection) Full Prescribing Information. Cubist Pharmaceuticals Lexington, MA (2003).
   Google Scholar
• TEDESCO KL, RYBAK MJ: Daptomycin. Pharmacotherapy (2004) 24:41–57.
   PubMed Web of Science ®Google Scholar
• CHA R, BROWN W, RYBAK MJ: Bactericidal activities of daptomycin, quinupristin-dalfopristin, and linezolid against vancomycin-resistant Staphylococcus aureusin an M vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob. Agents Chemother: (2003) 47(12):3960–3963.
   PubMed Web of Science ®Google Scholar
• •Comparison of daptomycin, linezolid and vancomycin activities against VRSA.
   Google Scholar
• BARRY AL, FUCHS PC, BROWN SD: In vitro activities of daptomycin against 2,789 clinical isolates from 11 North American medical centers. Antimicrob. Agents Chemother. (2001) 45:1919–1922.
   PubMed Web of Science ®Google Scholar
• RYBAK MJ, HERSHBERGER E, MOLD OVAN T, GRUCZ RG: In vitro of daptomycin, vancomycin, linezolid, and quinupristan-dalfopristan against staphylococci and enterococci, including vancomycin-intermediate and -resistant strains. Antimicrob. Agents Chemother. (2000) 44:1062–1066.
   PubMed Web of Science ®Google Scholar
• AKINS RL, RYBAK MJ: In vitro activities of daptomycin, arbekacin, vancomycin, and gentamicin alone and/or in combination against glycopeptide intermediate-resistant Staphylococcus aureusin an infection model.. Agents Chemother. (2000) 44: 1925-1929.
   Google Scholar
• KING A, PHILLIPS I: The M vitro activity of daptomycin against 514 Gram-positive aerobic clinical isolates. ". Antimicrob. Chemother: (2001) 48:219–223.
   Google Scholar
• FUCHS PC, BARRY AL, BROWN SD: vitro bactericidal activity of daptomycin against staphylococci. Antimicrob. Chemother: (2002) 49:467–470.
   Web of Science ®Google Scholar
• •Comparison of daptomycin, linezolid, quinupristin-dalfopristin, and vancomycin activities against staphylococci.
   Google Scholar
• CRITCHLEY IA, DRAGHI DC, SAHM DF, THORNSBERRY C, JONES ME, KARLOWSKY JA: Activity of daptomycin against susceptible and multidrug-resistant Gram-positive pathogens collected in the SECURE study (Europe) during 2000–2001.1 Antimicrob. Chemother: (2003) 51:639–649.
   Google Scholar
• ••Detailed survey of activities of daptomycin other antibiotics against European Gram-positive clinical isolates, broken out by resistance categories.
   Google Scholar
• WISE R, ANDREWS JM, ASHBY JP: Activity of daptomycin against Gram-positive pathogens: a comparison with other agents and the determination of a tentative breakpoint. ". Antimicrob. Chemother. (2001) 48:563–567.
   PubMed Web of Science ®Google Scholar
• SNYDMAN DR, JACOBUS NV, McDERMOTT LA, LONKS JR, BOYCE JM: Comparative M vitro activities of daptomycin and vancomycin against resistant Gram-positive pathogens.. Agents Chemother. (2000) 44:3447–3450.
   PubMed Web of Science ®Google Scholar
• PETERSEN PJ, BRADFORD PA, WEISS WJ, MURPHY TM, SUM PE, PROJAN SJ: hi vitro and M vivo activities of tigecycline (GAR-936), daptomycin, and comparative antibiotic agents against glycopeptide-intermediate Staphylococcus aureus and other resistant Gram-positive pathogens. Antimicrob. Agents Chemother. (2002) 46:2595–2601.
   PubMed Web of Science ®Google Scholar
• TEDESCO KL, RYBAK MJ: ha vitro activities of daptomycin, arbekacin and tigecycline (GAR-936) against several clinical glycopeptide-intermediate Staphylococcus species. 41st Annual Meeting of the Infectious Diseases Socieg, of America. San Diego, CA, USA (2003) (Abstract).
   Google Scholar
• AKINS RL, RYBAK MJ: Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureusisolates in an M vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob. Agents Chemother. (2001) 45:454–459.
   PubMed Web of Science ®Google Scholar
• CHANG S, SIEVERT DM, JC et al.: Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N Engl. J. Med. (2003) 348:1342–1347.
   PubMed Web of Science ®Google Scholar
• •Antibiotic susceptibility profile of the first isolated VRSA strain.
   Google Scholar
• TEDESCO KL, RYBAK MJ: Impact of inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, gentamicin and daptomycin in an in vitro pharmacodynamic model. Program and Abstracts of the 43rd Interscience Conference
   Google Scholar
• •• Antimicrobial Agents and Chemotherapy Chicago, IL, USA (2003) (Abstract A1151).
   Google Scholar
• TALLY FP, ZECKEL M, MM et al: Daptomycin: a novel agent for Gram-positive infections. Expert Opin. Investig. Drugs (1999) 8(8):1223–1238.
   PubMedGoogle Scholar
• OLESON FB Jr, BERMAN CL, KIRKPATRICK JB, REGAN KS, LAI J-J, TALLY FP: Once-daily dosing in dogs optimizes daptomycin safety. Antimicrob. Agents Chemother (2000) 44:2948–2953.
   PubMed Web of Science ®Google Scholar
• ••Pivotal in vivo studies detailingpharmacokinetics, skeletal muscle safety, and once-daily dosing rationale.
   Google Scholar
• ALBORN WE, ALLEN NE, DA: Daptomycin disrupts membrane potential in growing Staphylococcus aureus Antimicrob. Agents Chemother (1991) 35:2282–2287.
   PubMed Web of Science ®Google Scholar
• ALLEN NE, ALBORN WE, HOBBS JN: Inhibition of membrane potential-dependent amino acid transport by daptomycin. Antimicrob. Agents Chemother (1991) 35:2639–2642.
   PubMed Web of Science ®Google Scholar
• CANEPARI P, BOARETTI M: Lipoteichoic acid as a target for antimicrobial action. Microb. Drug Resist. (1996) 2:85–89.
   PubMed Web of Science ®Google Scholar
• LAGANAS V, ALDER J, SILVERMAN JA: In vitro bactericidal activities of daptomycin against Staphylococcus aureus and Enterococcus faecalis are not mediated by inhibition of lipoteichoic acid biosynthesis. Antimicrob. Agents Chemother: (2003) 47(8):2682–2684.
   PubMed Web of Science ®Google Scholar
• SILVERMAN JA, PERLMUTTER NG, SHAPIRO HM: Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus. Antimicrob. Agents Chemother: (2003) 47(8):2538–2544.
   PubMed Web of Science ®Google Scholar
• ••Describes the mechanism of action ofdaptomycin.
   Google Scholar
• WALE LJ, SHELTON AP, D: Scanning electron microscopy of Staphylococcus aureus and Enterococcus faecalis exposed to daptomycin. .1 Med. Microbiol (1989) 30(1):45–49.
   Google Scholar
• •Scanning electron microscope images of bacteria killed by daptomycin; provides further insights into its mechanism of action.
   Google Scholar
• NAU R, EIFFERT H: Modulation of release of proinflammatory bacterial compounds by antibacterials: potential impact on course of inflammation and in sepsis and meningitis. Clin. Microbiol Rev (2002) 15:95–110.
   PubMed Web of Science ®Google Scholar
• CARPENTER CE CHAMBERS HF: Daptomycin: another novel agent for treating infections due to drug-resistant Gram-positive pathogens. Clin. Infect. Dis. (2004) 38:994–1000.
   PubMed Web of Science ®Google Scholar
• COSTERTON JW, STEWART PS, GREENBERG EP: Bacterial biofilms: a common cause of persistent infections. Science (1999) 284:1318–1322.
   PubMed Web of Science ®Google Scholar
• JONES SM, MORGAN M, TJ, LAPPIN-SCOTT H: Effect of vancomycin and rifampicin on methicillin-resistant Staphylococcus aureus biofilms. Lancet (2001) 357:40–41.
   PubMed Web of Science ®Google Scholar
• COTTAGNOUD P, PFISTER M, COTTAGNOUD M et al.: Daptomycin is highly efficacious against penicillin-resistant and penicillin- and quinolone-resistant pneumococci in experimental meningitis by sterilizing the CSF within 4 hours. Abstracts of the 14th European Congress of Clinical Microbiology and Infectious Disease. Prague, Czech Republic (2004) (Abstract 896).
   Google Scholar
• HANBERGER H, NILSSON LE, MALLER R, ISAKSSON B: Pharmacodynamics of daptomycin and vancomycin on Enterococcus faecalis and Staphylococcus aureus demonstrated by studies of initial killing and postantibiotic effect and influence of Ca2+ and albumin on these drugs. Antimicrob. Agents Chemother (1991) 35:1710–1716.
   PubMed Web of Science ®Google Scholar
• NDA SUMMARY: Cubist. Lexington, MA, USA.
   Google Scholar
• SILVERMAN JA, OLIVER N, T, LI T: Resistance studies with daptomycin. Antimicrob. Agents Chemother. (2001) 45:1799–1802.
   PubMed Web of Science ®Google Scholar
• ••Key in vitro mutagenesis studies for Gram-positive organisms exposed to daptomycin.
   Google Scholar
• RAND KH, HOUCK H: Daptomycin synergy with rifampin and ampicillin against vancomycin-resistant enterococci. Antimicrob. Chemother (2004) 53(3):530–532.
   Web of Science ®Google Scholar
• •In vitro studies demonstrated synergy between daptomycin and rifarnpin and between daptomycin and ampicillin.
   Google Scholar
• LOUIE A, BALTCH AL, RITZ WJ, RP, ASPERILLA M: Comparison of M vitro inhibitory and bactericidal activities of daptomycin (LY146032) and four reference antibiotics, singly and in combination, against gentamicin-susceptible and high-level-gentamicin- enterococci. Chemotherapy (1993) 39:302–309.
   PubMed Web of Science ®Google Scholar
• BINGEN E, LAMBERT- N, LECLERCQ R, DOIT C, MARIANI-KURKDJIAN P: Bactericidal activity of vancomycin, daptomycin, ampicillin and aminoglycosides against vancomycin-resistant Enterococcus faecium.f. Antimicrob. Chemother: (1990) 26:619–626.
   PubMed Web of Science ®Google Scholar
• BINGEN E, DOIT C, LAMBERT-ZECHOVSKY N et al: Bactericidal activity of daptomycin against vancomycin-resistant Enterococcus faecium in an in vitro pharmacokinetic model. Eur. Clin. Microbiol Infect. Dis. (1991) 10:1062–1065.
   PubMed Web of Science ®Google Scholar
• RAND KH. HOUCK HJ: Daptomycin synergy with oxacillin against methicillin-resistant Staphylococcus aureus(MRSA). 103rd General Meeting of the American Socieg, for Microbiology Washington, DC, USA (2003).
   Google Scholar
• •Time-kill studies showing synergy with P-lactarns and daptomycin.
   Google Scholar
• ALDER J, ARBEIT R, EISENSTEIN B, TALLY F, HEINE H, SILVERMAN J: Pulmonary epithelial lining fluid (ELF) as a privileged site: daptomycin in pulmonary infections. 11th International Congress on Infectious Diseases. Cancun, Mexico (2004) (Abstract 00825).
   Google Scholar
• DVORCHIK B, DAMPHOUSSE D: Single-dose pharmacokinetics of daptomycin in young and geriatric.Pharmacol (2004)44:612–620.
   Web of Science ®Google Scholar
• ARBEIT RD, MAKI D, TALLY FP, CAMPANARO E, EISENSTEIN BI: FOR THE THE DAPTOMYCIN 98-01 AND 99-01 INVESTIGATORS: The safety and efficacy of daptomycin in the treatment of complicated skin and skin structure infections. Clin. Infect. Dis. (2004) 38:1673–1681.
   PubMed Web of Science ®Google Scholar
• ••Report of large clinical trials. The basis fordaptomycin indication against cSSSI.
   Google Scholar
• DATA ON FILE. Cubist Pharmaceuticals: Clinical Study Report: Protocol DAP-RCC–9804.
   Google Scholar
• NABER K, EISENSTEIN B, TALLY FP: Daptomycin versus ciprofloxacin in the treatment of complicated urinary tract infection due to Gram-positive bacteria. Infect. Dis. Clin. Piaci (2004) (In press).
   Google Scholar
• HEINE HS, BASSETT J, MILLER L, ANDREWS GP, BYRNE WR: Efficacy of daptomycin against Bacillus anthracis (Anthrax) in a murine model of anthrax-spore inhalation. 104th General Meeting of the American Socieg, for Microbiology New Orleans, LA, USA (2004) (Abstract A–051).
   Google Scholar
• CHAMBERS HF: The changing epidemiology of Staphylococcus aureus? Emerg. Infect. Dis. (2001) 7:178–182.
   Google Scholar
• CENTERS FOR DISEASE CONTROL AND PREVENTION: Outbreaks of community-acquired methicillin-resistant Staphylococcus aureus skin infections — Los Angeles County, California, 2002 — 2003. MMWR Moth. Mortal. Wkly Rep. (2003) 55:88.
   Google Scholar
• SALGADO CD, FARR BM, CALFEE DP: Community-acquired methicillin-resistant Staphylococcus aureus: A meta-analysis of prevalence and risk factors. Clin. Infect. Dis. (2003) 36:131–139.
   PubMed Web of Science ®Google Scholar
• IYER S, JONES DH: Community-acquired methicillin-resistant Staphylococcus aureus skin infections: A retrospective analysis of clinical presentation and treatment of a local. J. Am. Acad. Dermatol (2004) 50:854–858.
   PubMed Web of Science ®Google Scholar
• NAIMI TS, LEDELL KH,-SABETTI K et al.: Comparison of community- and health care-associated methicillin-resistant Staphylococcus atoms infection. JAMA (2003) 290:2976–2984.
   Google Scholar
• TENOVER FC, BIDDLE JW, MV: Increasing resistance to vancomycin and other glycopeptides in Staphylococcus atoms. Emerg. Infect. Dis. (2001) 7:327–332.
   PubMed Web of Science ®Google Scholar
• FRIDKIN SK, HAGEMAN J, MCDOUGAL LK et al.: For the vancomycin-intermediate Staphylococcus aureus Epidemiology Study Group: epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001. Clin. Infect. Dis. (2003) 36:429–439.
   PubMed Web of Science ®Google Scholar
• SMITH TL, PEARSON ML, KR et al: For the glycopeptide- Staphylococcus aureus Working Group: emergence of vancomycin resistance in Staphylococcus atoms. N Engl J. Med. (1999) 340:493–501.
   PubMed Web of Science ®Google Scholar
• SAKOULAS G, MOISE-BRODER PA, SCHENTAG J, FORREST A, MOELLERING RC Jr, GM: Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia.. Microbial. (2004) 42:2398–2402.
   Web of Science ®Google Scholar
• GELFAND MS, CLEVELAND KO: Vancomycin therapy and the progression of methicillin-resistant Staphylococcus atoms vertebral osteomyelitis. South. Med. J. (2004) 97:593–597.
   PubMedGoogle Scholar